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ABSTRACT
Objective: The purpose ofthis study was to compare the accuracy ofcommonly used methods for the
detection ofrubella immunity, especially the fully automated IMx assay.
Methods:A total of 190 sera (101 immune and 89 non-immune) submitted to Harrisburg Hospital
or Polyclinic Medical Center for the determination of rubella immunity were tested by enzyme
immunoassay (IMx and Rubazyme, Abbott Diagnostic Laboratories, North Chicago, IL), indirect
immunofluorescence (FIAX, Whittaker Bioproducts, Walkersville, MD), and latex agglutination
(Rubascan, Becton Dickinson Microbiology Systems, Cockeysville, MD, and Rubalex, Wellcome
Diagnostics, Research Triangle Park, NC). Specimens were frozen at -30C until the study was
initiated. Each ofthe assays was performed according to the manufacturers’ specifications. Sensitiv-
ity, specificity, accuracy, and positive and negative predictive values for each assay were calculated
using a consensus result of the 5 methods tested.
Results: The sensitivity, specificity, and accuracy, respectively, of the test systems were as fol-
lows: IMx, 96%, 97%, and 96%; Rubazyme, 100%, 99%, and 99%; Rubascan, 100%, 98%, and 99%;
Rubalex, 99%, 97%, and 98%; and FIAX 90%, 100%, and 95%. False negative reactions were seen
with the FIAX system.
Conclusions: The IMx system, a new "walk away" system from Abbott Diagnostic Laboratories
and the Rubazyme systems performed well; however the latex agglutination tests proved to be the
most rapid and convenient methods for screening sera for the presence of rubella immunity.
(C) 1994 Wiley-Liss, Inc.
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ublic health measures to reduce the transmission
of rubella are dependent upon the vaccination of
children > 12 months of age, school-age children
not previously immunized, and susceptible adults.
The occurrence of rubella during pregnancy can
result in severe congenital abnormalities ofthe new-
born. Current guidelines suggest that women of
childbearing age should be evaluated for immune
status to rubella. If they are negative, they should
be monitored throughout the pregnancy for sero-
conversion. If these women remain negative fol-
lowing delivery, then they should be vaccinated
postpartum. In addition, health care personnel are
monitored at most pre-employment physicals; if
they are found to be non-immune, vaccination is
recommended. The rubella antibody test is one of
the most frequently ordered tests in the serology
laboratory.
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In the past, the recommended method for deter-
mining immune status to rubella was the hemagglu-
tination inhibition (HI) test. For the most part, HI
has been replaced with less cumbersome methods,
including passive hemagglutination,
1-5 latex agglu-
tination,
1-13 fluorescenceimmunoassay,
1--4,6,14,15
enzyme immunoassay,
1,2,4,5,10, 1,15--18 and radial
hemolysis in gel. 4’13 These methods have been
shown to be as accurate as HI and in some cases
more sensitive, specific, and reproducible, s’8’9’11
Recently, a fully automated IMx immunoassay
analyzer was developed for the detection of IgG
and IgM antibodies to rubella virus.
16,19 A fully
automated system provides for a more objective
result, decreases the technical time and cost re-
quired to perform the assay, offers standardization
of the test procedure, and lends itself to physician
office testing. The purpose of this study was to
compare several commercially available methods
for the determination of rubella immunity, includ-
ing the fully automated IMx immunoassay ana-
lyzer.
MATERIALS AND METHODS
Specimens
A total of 190 serum specimens submitted to the
clinical microbiology laboratory at Harrisburg
Hospital and Polyclinic Medical Center were tested
by 5 methods. The serum samples were obtained
from specimens submitted for rubella serology. Sera
were tested on receipt in the laboratory by fluores-
cence immunoassay (FIAX, Whittaker Bioprod-
ucts, Waldersville, MD) and latex agglutination
(Rubascan, Becton Dickinson Microbiology Sys-
tems, Cockeysville, MD) and then were stored at
-30C until subsequent testing. The stored sera
remained frozen for 6 months and then were tested
using the remainder of the assays.
IMx
The IMx (Abbott Diagnostic Laboratories, North
Chicago, IL) is an automated procedure based on
microparticle enzyme immunoassay technology.
Once the serum sample is placed into the reaction
cell of the carousel, all additional steps are per-
formed by the instrument. The principle and oper-
ation of the IMx have been described previ-
ously6,18 and are reviewed briefly here. Once
controls and samples have been loaded onto the
carousel and the instrument started, the probe/
electrode assembly delivers the sample and diluent
buffer to the predilution well of the reaction cell.
Next, the microparticles coated with rubella virus
and an aliquot ofthe diluted sample are added to the
incubation well. If antibodies to rubella are present
in the patient’s serum, they will bind to the antigen-
coated microparticle forming an antigen-antibody
complex. Diluent buffer is added to the reaction
mixture, and an aliquot of the antigen-antibody
complex is added to the glass fiber matrix. The
microparticles bind irreversibly to the glass fiber
matrix. The matrix is washed to remove unbound
material, and an alkaline phosphatase-conjugated
anti-human IgG is dispensed onto the matrix and
binds to the antigen-antibody complex. The matrix
is then washed again to remove unbound material.
The substrate 4-methylumbelliferyl phosphate is
then added to the matrix, and the fluorescent prod-
uct formed is measured by the optical assembly of
the instrument. Those specimens that exhibited val-
ues > 10 IU of IgG antibody to rubella virus were
considered immune. At the beginning of the study,
6 calibrators were run to establish a calibration
curve. Once established, this calibration curve has
been shown to be stable for at least 2 weeks. Posi-
tive and negative controls were included in each
run.
FlAX
Fluorescence immunoassay was performed using
Rubella G kits supplied by the manufacturer. The
method was performed according to the manufac-
turer’s instructions and has been described previ-
ously. s A result lower than 8 indicated susceptibil-
ity to rubella and a result greater than 12 indicated
immunity. An equivocal zone of 8-12 has been
established by the manufacturer to avoid false posi-
tive readings, and serum specimens in this range
were retested.
Latex Agglutination
Latex agglutination was performed using the
Rubascan and Rubalex (Wellcome Diagnostics, Re-
search Triangle Park, NC). Both procedures were
tested according to the manufacturers’ instructions
and have been described previously. 2’6 Serum spec-
imens tested with the Rubalex method were diluted
1:10 prior to testing. With the Rubascan method,
serum samples were tested undiluted and diluted
1:10 as recommended by the manufacturer.
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TABLE I. Performance characteristics (%) of the 5 methods for determining rubella immune status
Method Sensitivity Specificity PP NP Accuracy
IMx 96 (97/101) 97 (86/89) 96 (97/101) 96 (86/90) 96 (183/190)
FlAX 90 (89/99)* 100 (89/89) 100 (89/89) 90 (89/99) 95 (I 78/188)
Rubascan 100 (101/101) 98 (87/89) 98 (101/103) 100 (87/87) 99 (188/190)
Rubalex 99 (100/101) 97 (86/89) 97 (100/103) 99 (86/87) 98 (186/190)
Rubazyme 100 (101/101) 99 (88/89) 99 (101/102) 100 (88/88) 99 (189/190)
aTwo specimens gave equivocal results using the FlAX method and were elminated from the comparison.
*P 0.0008.
TABLE 2. Samples with discrepant results
Final No. of
IMx FlAX Rubascan Rubalex Rubazyme interpretation samples
Negative Negative Positive Positive Negative Negative 2
Positive Negative Positive Positive Positive Positive 4
Positive Equivocal Positive Positive Positive Positive 2
Negative Negative Positive Positive Positive Positive 4
Positive Negative Negative Negative Negative Negative 2
Positive Positive Positive Negative Positive Positive
Negative Negative Negative Positive Negative Negative
Positive Negative Negative Negative Positive Negative
Enzyme Immunoassay (EIA)
EIA was performed using Rubazyme (Abbott Di-
agnostic Laboratories) kits supplied by the manu-
facturer. The method was performed and the
results were interpreted according to the manu-
facturer’s instructions and have been descr’bed pre-
viously, s Each serum sample was tested in dupli-
cate.
Comparison of Results and Statistical Analysis
Specimens were considered positive or negative for
rubella antibody when 3 or more methods were in
agreement. Each assay method was compared to the
"consensus" result in order to determine sensitivity,
specificity, accuracy, and predictive values of the
method. Statistical analysis and evaluation of the 5
methods were made using the chi-square test
(StatView + Graphics, Abacus Concepts, Inc.,
Berkeley, CA).
RESULTS
Using a consensus of 3 or more methods, we found
a total of 101 specimens to be positive for rubella
antibody and 89 specimens to be negative. Perfor-
mance characteristics of the methods for the detec-
tion of rubella antibody can be seen in Table 1.
The FIAX, with a sensitivity of 90%, was the
least sensitive of the methods evaluated
(P 0.0008). The other 4 methods were compa-
rable in sensitivity, which ranged from 96% to
100%. The specificity, positive predictive value
(PPV), negative predictive value (NPV), and accu-
racy of the 5 methods were as follows: 97%, 96%,
96%, 96% for IMx; 100%, 100%, 90%, 95% for
FIAX; 98%, 98%, 100%, 99% for Rubascan; 97%,
97%, 99%, 98% for Rubalex; and 99%, 99%,
100%, 99% for Rubazyme. There was no statisti-
cally significant difference in specificity in the 5
methods (P 0.3158).
Data on samples giving discrepant results are
found in Table 2. There were 17 samples that gave
discrepant results in assays. Four samples were neg-
ative, and 2 were equivocal (even on repeat testing)
by the FIAX method but positive by the other 4
methods. Four additional samples were negative by
FIAX and IMx but positive by all other methods.
The other 7 discrepancies were distributed among
the other assays.
DISCUSSION
The Advisory Committee for Immunization Prac-
tices of the Center for Disease Control, Atlanta,
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GA, has recommended that a positive result by any
test for rubella antibody be accepted as evidence of
rubella immunity,z In support of this recommen-
dation are several studies that have shown that low
antibody titers, particularly those detected by latex
agglutination, are sufficient to protect against in-
fection with attenuated virus. 8’1z The latex aggluti-
nation methods (Rubascan and Rubalex), as dem-
onstrated in this study, are as sensitive, specific,
and accurate as other methodologies. They also have
the advantages of requiring no pretreatment of se-
rum samples, small sample volume, rapid turn-
around time (less than 10 min), and no purchase of
capital equipment.
The 3 remaining assays are either fully auto-
mated (IMx) or semiautomated (FIAX and Ruba-
zyme). Previous studies on the fully automated
IMx rubella IgG assay have shown that the system
is more sensitive than and as specific as conven-
tional EIA technology.
16,18 Schaefer et al.
8 showed
that the IMx had a sensitivity of 99.9% compared
to a sensitivity of 96.5% for Rubazyme. Specificity
was identical for both assays at 98.9%. Similar
results were obtained by Abbott et al.
16 and Skurrie
et al.
19 In these previous studies, the IMx was only
compared to conventional EIA with discordant re-
sults referred by passive hemagglutination. Other
commercially available systems such as latex agglu-
tination and fluorescent immunoassay were not eval-
uated. In the present study, the IMx was found to
be more sensitive and accurate than fluorescent im-
munoassay but equivalent to the latex agglutination
assays and conventional EIA.
The primary purpose of rubella screening is to
identify non-immune women of childbearing age.
Therefore, a false positive result would be an error
with the most serious consequences since women
who are truly non-immune would not be vaccinated
and would be fully susceptible to rubella infection.
Subsequent infection during pregnancy would pose
a risk to the unborn fetus. On the other hand, a
false negative result, although not as serious, could
result in potential morbidity to the patient due to
unnecessary vaccination. The FIAX method showed
the lowest diagnostic accuracy (95%), primarily
due to a 10% false negative rate. The other methods
evaluated had diagnostic accuracies ranging from
96% to 99%, with few false positive or false nega-
tive results. On the basis of the results presented
here, all ofthe methods evaluated, with the possible
exception of the FIAX assay, can be used reliably to
determine rubella immune status.
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